Curasight has received approval from European Medicines Agency (EMA) for its Clinical Trial Application (CTA) for a Phase I study with uTREAT in glioblastoma. The study is the first clinical trial of uTREAT from the company's treatment platform. The approval means that Curasight now has clinical development in both diagnostics (uTRACE) and therapy (uTREAT). The first patient is expected to be dosed in the fourth quarter of 2025.
|
Published August 26, 2025
Curasight receives approval for Phase I study with uTREAT
Notes
OssDsign signs agreement in the western US
Annexin doses first patients in phase IIa study
Boule Diagnostics CEO leaves the company
Flerie divests Limited Partnership segment
Cantargia reports survival results from TRIFOUR
Guard Therapeutics explores strategic options
Thor Medical signs supply agreement with RadioMedix
NEWSLETTER
Today's news roundup
The news sweep Friday 05 December
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
BiBBInstruments validates clinical need during US tour
Sunstone sounds the alarm: “Danish startups are running on fumes”
Sprint Bioscience: "We have shown it is possible to make early deals"
How to take medtech to market – tips from those who have succeeded
Flerie seeks to merge with Lipum – creating a private platform for the next development phase of SOL-116
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account